Inhibition of Haspin Kinase Promotes Cell-Intrinsic and Extrinsic Antitumor Activity.
Saved in:
| Title: | Inhibition of Haspin Kinase Promotes Cell-Intrinsic and Extrinsic Antitumor Activity. |
|---|---|
| Authors: | Melms JC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Columbia University Medical Center, Division of Hematology and Oncology, New York, New York.; Columbia Center for Translational Immunology, New York, New York., Vallabhaneni S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts., Mills CE; Laboratory for Systems Pharmacology, Harvard Medical School, Boston, Massachusetts., Yapp C; Laboratory for Systems Pharmacology, Harvard Medical School, Boston, Massachusetts., Chen JY; Laboratory for Systems Pharmacology, Harvard Medical School, Boston, Massachusetts., Morelli E; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Waszyk P; Experimental Pathology Service, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland., Kumar S; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Immunology, Harvard Medical School, Boston, Massachusetts., Deming D; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts., Moret N; Laboratory for Systems Pharmacology, Harvard Medical School, Boston, Massachusetts., Rodriguez S; Laboratory for Systems Pharmacology, Harvard Medical School, Boston, Massachusetts., Subramanian K; Laboratory for Systems Pharmacology, Harvard Medical School, Boston, Massachusetts., Rogava M; Columbia University Medical Center, Division of Hematology and Oncology, New York, New York.; Columbia Center for Translational Immunology, New York, New York.; Laboratory for Systems Pharmacology, Harvard Medical School, Boston, Massachusetts., Cartwright ANR; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts., Luoma A; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts., Mei S; Laboratory for Systems Pharmacology, Harvard Medical School, Boston, Massachusetts., Brinker TJ; National Center for Tumor Diseases (NCT), German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Dermatology, University Hospital Heidelberg, Heidelberg, Germany., Miller DM; Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts., Spektor A; Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Schadendorf D; Department of Dermatology, University Hospital Essen and German Cancer Consortium (DKTK), Essen, Germany., Riggi N; Experimental Pathology Service, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland., Wucherpfennig KW; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Immunology, Harvard Medical School, Boston, Massachusetts., Sorger PK; Laboratory for Systems Pharmacology, Harvard Medical School, Boston, Massachusetts.; Ludwig Center for Cancer Research at Harvard, Boston, Massachusetts., Izar B; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. Bi2175@cumc.columbia.edu.; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Columbia University Medical Center, Division of Hematology and Oncology, New York, New York.; Columbia Center for Translational Immunology, New York, New York.; Laboratory for Systems Pharmacology, Harvard Medical School, Boston, Massachusetts.; Ludwig Center for Cancer Research at Harvard, Boston, Massachusetts.; Broad Institute of MIT and Harvard, Cambridge, Massachusetts. |
| Source: | Cancer research [Cancer Res] 2020 Feb 15; Vol. 80 (4), pp. 798-810. Date of Electronic Publication: 2019 Dec 27. |
| Publication Type: | Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 2984705R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1538-7445 (Electronic) Linking ISSN: 00085472 NLM ISO Abbreviation: Cancer Res Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
